Press Releases
Palleon to Present New Findings on Colorectal Tumor Microenvironment Identified with its HYDRA Platform at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023
Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial
Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor
Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day
Palleon Announces Issuance of a U.S. Patent for Use of Antibody Sialidase Conjugates
Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase
Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
Palleon Presents Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase
Palleon Pharmaceuticals to Present Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase at AACR Annual Meeting
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology
Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology
Palleon Pharmaceuticals Appoints Denis Patrick to its Board of Directors
Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity
Palleon Pharmaceuticals Appoints David Johnson to its Board of Directors
Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting
Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer
Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors
Palleon Pharmaceuticals Appoints Nikola Trbovic to its Board of Directors
Palleon Pharmaceuticals Appoints Deepa Pakianathan, Ph.D., to its Board of Directors
Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases
Palleon Pharmaceuticals Appoints Li Peng, Ph.D., as Chief Scientific Officer
Palleon Pharmaceuticals to Present Preclinical Data on EAGLE-Her2 and Anti-Siglec-9 Antibody Programs at the 11th Annual Protein & Antibody Engineering Summit
Palleon Pharmaceuticals to Present Preclinical Data on EAGLE and HYDRA Platforms at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
Palleon Pharmaceuticals Announces Successful Defense of European Patent
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the AACR Special Conference on Tumor Immunology and Immunotherapy
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
Palleon Pharmaceuticals Appoints Lori Hu of Vertex Ventures HC to Board of Directors
Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer
Palleon Pharmaceuticals Raises $47.6 million to Develop Glycoimmune Checkpoint Inhibitors, a New Class of Medicines Designed to Overcome Resistance to First-Generation Immuno-Oncology Drugs
